Broad-spectrum pathogenic bacteria

Broad-spectrum pathogenic bacteria refers to a diverse array of bacterial species, including both Gram-positive and Gram-negative organisms, that are capable of causing disease in human hosts (NIH, 2023). This term does not describe a single molecular target, such as a specific receptor or enzyme, but rather a broad clinical category of pathogens that are susceptible to broad-spectrum antimicrobial agents (StatPearls, 2023). These bacteria utilize a variety of biological processes to survive and proliferate, including peptidoglycan cell wall synthesis, ribosomal protein translation, and DNA replication via topoisomerases (PubMed, 2022). In a clinical context, these pathogens are responsible for a wide spectrum of infections, including pneumonia, urinary tract infections, and life-threatening sepsis (WHO, 2021). Broad-spectrum antibiotics, such as carbapenems, fluoroquinolones, and tetracyclines, interact with these organisms by targeting highly conserved bacterial components that are absent or significantly different in human cells (PubChem, 2024). While these agents are essential for empirical therapy, their use presents significant therapeutic challenges, most notably the selection for multi-drug resistant strains and the collateral destruction of the protective human microbiome (CDC, 2022).

Other names

Gram-positive and Gram-negative bacteriaPathogenic bacteriaMulti-species bacterial pathogensBroad-spectrum pathogens

Broad-spectrum antibiotics target conserved bacterial processes, including cell wall synthesis (via inhibition of peptidoglycan cross-linking), protein synthesis (via binding to the 30S or 50S ribosomal subunits), and nucleic acid synthesis (via inhibition of DNA gyrase or topoisomerase IV) (StatPearls, 2023).